Table 3.
Quality Assessment of Included Studies
Study | Prospective Data Collection | Description of Selection Criteria | Assessment of Baseline PAD Severity | Detailed Population Characteristics | Follow‐Up ≥4 Years | ≥90% of Participants Included in Final Analysis | Comprehensive Mortality Assessment* | Adjustment for Population Stratification |
---|---|---|---|---|---|---|---|---|
Jain et al8 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Leeper et al19 | Yes | No | No | Yes | Yes | Yes | Yes | No |
Jain et al18 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
McDermott et al21 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
McDermott et al20 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes |
Singh et al24 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
de Liefde et al25 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Sakamato et al23 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Gardner et al17 | No | Yes | Yes | Yes | Yes | N/A | Yes | No |
McDermott et al22 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
N/A indicates not applicable due to retrospective study design; PAD, peripheral artery disease.
Considered comprehensive if mortality status was searched on a Social Security death register or if proxies of study participants were contacted.